Therapy Areas: AIDS & HIV
Tezepelumab Is The First Biologic to Significantly Reduce Exacerbations in Broad Population of Patients With Severe, Uncontrolled Asthma
1 March 2021 - - US-based biotechnology company Amgen (NASDAQ: AMGN) and British–Swedish pharmaceutical and biopharmaceutical company AstraZeneca (OTC: AZNCF) have released positive full results from the pivotal NAVIGATOR Phase 3 trial, which showed the potential of tezepelumab to be a first-in-class medicine in severe asthma, the companies said.

When added to standard of care, tezepelumab demonstrated a statistically significant and clinically meaningful reduction in the annualized asthma exacerbation rate in patients with severe, uncontrolled asthma, compared to placebo.

The results were presented at the American Academy of Asthma Allergy and Immunology annual meeting. NAVIGATOR is a pivotal Phase 3 trial that will form the basis of regulatory filing.

Tezepelumab, a potential first-in-class medicine, when added to standard of care achieved a 56% reduction (p
Login
Username:

Password: